Journal article
Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS‐ACTS Substudy
Abstract
BACKGROUND: The efficacy, safety, and ease of use of rivaroxaban may reduce anticoagulation-treatment burden and improve nonvalvular atrial fibrillation (NVAF) patient satisfaction compared with vitamin K antagonists (VKAs).
HYPOTHESIS: Transitioning from a VKA to rivaroxaban improves treatment satisfaction in routine practice.
Authors
Coleman CI; Haas S; Turpie AGG; Kuhls S; Hess S; Evers T; Amarenco P; Kirchhof P; Camm AJ; Investigators OBOTX
Journal
Clinical Cardiology, Vol. 39, No. 10, pp. 565–569
Publisher
Wiley
Publication Date
October 2016
DOI
10.1002/clc.22565
ISSN
0160-9289